Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma

Pediatric Blood and Cancer

Volumn 50, Issue 4, 2008, Pages 752-756

  Ferrari, Stefano ^a   Zanella, Licciana ^a   Alberghini, Marco ^a   Palmerini, Emanuela ^a   Staals, Eric ^a   Bacchini, Patrizia ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Chemotherapy; Ezrin; Immunohistochemistry; Osteosarcoma

Indexed keywords

ALKALINE PHOSPHATASE; CISPLATIN; DOXORUBICIN; EZRIN; IFOSFAMIDE; LACTATE DEHYDROGENASE; MESNA; METHOTREXATE;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CHILD; DISEASE FREE SURVIVAL; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR BIOPSY;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYTOSKELETAL PROTEINS; DISEASE-FREE SURVIVAL; EXTREMITIES; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOADJUVANT THERAPY; OSTEOSARCOMA; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 40449110894     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21360     Document Type: Article

References (20)

1. Campanacci M. High grade osteosarcomas. In: Campanacci M, editor. Bone and soft tissue tumors, 2nd edition. Wien, New York: Springer-Verlag; 1999. pp 463-515.
2. Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: Results of the Memorial Sloan-Kettering (T-12) protocol. J Clin Oncol 1998;16:2452-2458.
3. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the cooperative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998;9:893-899.
4. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: An updated report. J Clin Oncol 2000;18:4016-4027.
5. McClatchey AI. Merlin and ERM proteins: Unappreciated roles in cancer development? Nat Rev Cancer 2003;3:877-883.
6. Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: Integrators at the cell cortex. Nat Rev Mol Cell Biol 2002;3:586-599.
7. Curto M, McClatchey AI. Ezrin. . .a metastatic detERMinant? Cancer Cell 2004;5:113-114.
8. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004;10:182-186.
9. Geiger KD, Stoldt P, Schlote W, Derouiche A. Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in ologodendrogliomas. Am J Pathol 2000;157:1785-1793.
10. Ilmonen S, Vaheri A, Asko-Seljavaara S, Carpen O. Ezrin in primary cutaneous melanoma. Mod Pathol 2005;18:503-510.
11. Valdman A, Fang X, Pang ST, et al. Ezrin expression in prostate cancer and benign prostatic tissue. Eur Urol 2005;48:852-857.
12. Makitie T, Carpen O, Vaheri A, Kivela T. Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma. Invest Ophthalmol Vis Sci 2001;42:2442-2449.
13. Weng WH, Ahlen J, Astrom K, et al. Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res 2005;11:6198-6204.
14. Park H-R, Jung WW, Bacchini P, et al. Ezrin in osteosarcoma: Comparison between conventional high-grade and central low-grade osteosarcoma. Pathol Res Pract 2006;202:509-515.
15. Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: A joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005;23:8845-8852.
16. Picci P, Bacci G, Campanacci M, et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer 1985;56:1515-1521.
17. Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006;106:1154-1161.
18. Zeng H, Xu L, Xiao D, et al. Altered expression of ezrin in esophageal squamous cell carcinoma. J Histochem Cytochem 2006;54:889-896.
19. Eccles SA, Welch DR. Metastasis: Recent discoveries and novel treatment strategies. Lancet 2007;369:1742-1757.
20. Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005;65:2406-2411.